Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.82 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.69 |
| ▸ | PYGL | P06737 | 1/20 | 0.56 |
| ▸ | MPG | P29372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500738 | 1.00 | GBA1 (0.82) | GBA1FUCA1PYGLMPG | |
| SCHEMBL500739 | 1.00 | GBA1 (0.82) | GBA1FUCA1PYGLMPG | |
| SCHEMBL2713933 | 0.90 | GBA1 (1.00) | GBA1FUCA1PYGL | |
| SCHEMBL5327603 | 0.90 | GBA1 (1.00) | GBA1FUCA1PYGL | |
| SCHEMBL8186647 | 0.90 | GBA1 (1.00) | GBA1FUCA1PYGL | |
| SCHEMBL742926 | 0.89 | GBA1 (0.75) | GBA1FUCA1 | |
| SCHEMBL1190716 | 0.89 | GBA1 (0.75) | GBA1FUCA1 | |
| SCHEMBL14759416 | 0.89 | GBA1 (0.75) | GBA1FUCA1 | |
| SCHEMBL14759418 | 0.89 | GBA1 (0.75) | GBA1FUCA1 | |
| SCHEMBL505547 | 0.85 | GBA1 (0.66) | GBA1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183019-B2 | (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine; enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone; for purine nucleoside phosphorylase (PNP) inhibitors | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-22 | — | — | US | disclosed |
| US-20090325986-A1 | Deazapurine Analogs of 1'-Aza-L-Nucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | disclosed |
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280334-A1 | Method for Preparing 3-Hydroxy-4-Hydroxymethyl-Pyrrolidine Compounds | HPD, DHPS, CYP3A5 | GBA1 2125/4885FUCA1 1020/4885PYGL 518/4885 |
| US-20090325986-A1 | Deazapurine Analogs of 1'-Aza-L-Nucleosides | TPMT, TYMP, DUT | GBA1 707/4885FUCA1 893/4885PYGL 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.